Which CGRP monoclonal antibody is ligand-targeting and used for migraine prevention?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which CGRP monoclonal antibody is ligand-targeting and used for migraine prevention?

CGRP therapies work by either blocking the CGRP peptide itself or blocking the CGRP receptor. The antibody that binds the CGRP ligand prevents the peptide from activating its receptor, which lowers migraine frequency and provides preventive benefit. Fremanezumab is a monoclonal antibody that targets the CGRP ligand, making it ligand-targeting and effective for migraine prevention. Erenumab, by contrast, targets the CGRP receptor itself, so it’s receptor-targeting rather than ligand-targeting. The other two agents listed are gepants, small-molecule CGRP receptor antagonists, not monoclonal antibodies, and they are used mainly for acute treatment rather than long-term prevention. So, fremanezumab is the ligand-targeting CGRP monoclonal antibody used for migraine prevention.

CGRP therapies work by either blocking the CGRP peptide itself or blocking the CGRP receptor. The antibody that binds the CGRP ligand prevents the peptide from activating its receptor, which lowers migraine frequency and provides preventive benefit. Fremanezumab is a monoclonal antibody that targets the CGRP ligand, making it ligand-targeting and effective for migraine prevention.

Erenumab, by contrast, targets the CGRP receptor itself, so it’s receptor-targeting rather than ligand-targeting. The other two agents listed are gepants, small-molecule CGRP receptor antagonists, not monoclonal antibodies, and they are used mainly for acute treatment rather than long-term prevention.

So, fremanezumab is the ligand-targeting CGRP monoclonal antibody used for migraine prevention.

More practice questions